Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 121, Issue 4, Pages 1231-1241Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI44145
Keywords
-
Categories
Funding
- NIH-NCI [5-R01-CA-105118-04]
- Doris Duke Charitable Foundation
Ask authors/readers for more resources
Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR in cancers. Here we provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathways gives us.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available